Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission
- 24 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (7) , 995-1002
- https://doi.org/10.1097/01.aids.0000222071.60620.1d
Abstract
Single-dose nevirapine (sd-NVP) for prevention of mother-to-child HIV-1 transmission is associated with selection of resistant viral variants, particularly the Lysine (K) to Asparagine (N) mutation at codon 103 (K103N) of reverse transcriptase. As this may influence subsequent treatment responses, a better understanding of the dynamics of decay and persistence of this variant is needed. We measured the frequency of K103N mutants among a cohort of HIV-1-infected pregnant women recruited at an out-patient clinic in Johannesburg, South Africa. Samples taken 6 weeks, 3, 7 and 12 months after delivery from 67 HIV-1-infected women who received sd-NVP during labor to prevent transmission were analyzed. Quantification of K103N mutants in maternal plasma viral RNA and cellular DNA was done using an allele-specific real-time polymerase chain reaction assay capable of detecting codons AAC and AAT if their frequency was > 0.002 of the total viral population. Using the allele-specific assay, 87.1% (27/31) of RNA samples and 52.3% (23/44) of DNA samples collected 6 weeks after sd-NVP had detectable K103N variants. This declined to 65.4% (17/26), 38.9% (14/36), and 11.3% (6/53) in RNA at 3, 7 and 12 months respectively, and to 4.2% (2/48) in DNA at 12 months. K103N resistant variants were present in almost all women at 6 weeks post-sd-NVP but declined rapidly over time. Resistant variants were detected less frequently in cellular DNA with persistence in this compartment by 12 months post-sd-NVP among only a minority.Keywords
This publication has 18 references indexed in Scilit:
- Sensitive Drug‐Resistance Assays Reveal Long‐Term Persistence of HIV‐1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single‐Dose NVP: HIVNET 012The Journal of Infectious Diseases, 2005
- Emergence of Drug‐Resistant HIV‐1 after Intrapartum Administration of Single‐Dose Nevirapine Is Substantially UnderestimatedThe Journal of Infectious Diseases, 2005
- Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype AnalysisJournal of Clinical Microbiology, 2005
- Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral TherapyNew England Journal of Medicine, 2004
- Competitive Fitness of Nevirapine-Resistant Human Immunodeficiency Virus Type 1 MutantsJournal of Virology, 2004
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trialThe Lancet, 2003
- Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316The Journal of Infectious Diseases, 2002
- Antiretroviral Prophylaxis of Perinatal HIV-1 Transmission and the Potential Impact of Antiretroviral ResistanceJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Impact of Human Immunodeficiency Virus Type 1 (HIV‐1) Subtype on Women Receiving Single‐Dose Nevirapine Prophylaxis to Prevent HIV‐1 Vertical Transmission (HIV Network for Prevention Trials 012 Study)The Journal of Infectious Diseases, 2001
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999